Taiwanese Claims data study shows the risk of opportunistic infection in ~77K autoimmune pts shows OI highes in PM/DM cases (61.3/1000PY), followed by SLE (43.1/1000PY), SSc (31.6), RA (25), and pSS (24.1). OI risk highest during 1st year https://t.co/YKP7ZF7FIx

Logical + Data-driven = Annoying. (If you have high standards does that make you arrogant?)

China retrospective study of 727 SoA abd 857 RA pts shows risk of H. Zoster same between SpA & RA (aHZ=0.97), but was significantly higher with MTX (adj HR 3.47) and infliximab (adj HR 10.67) https://t.co/gpictKPpIT

FDA grants breakthrough status to OFEV (nintedanib) forthe treatment of chronic fibrosing interstitial lung diseases (ILDs), other than idiopathic pulmonary fibrosis (which it is currently approved for). Nintedanib has been studied in PSS ILD. https://t.co/K0ZTyqrfh6

@LCalabreseDO @GoutEducation @CreakyJoints @LarryEdwardsMD @CCalabreseDO @RheumJC Sacrilegious but true. Every MD thinks they are great-they learned it in med school & as a PGY*.